Response to US study of CAR-T in childhood brain tumors
On 14 November 2024 Dutch national newspaper De Volkskrant writes about an American study into CAR-T for children with a brain tumor, and also features comment from Jasper van der Lugt and Friso Calkoen, pediatric oncologists at the Princess Máxima Center.
One of the eleven children and young adults with the incurable brain tumor DIPG who received CAR-T cell therapy appears to have been cured. Four years after the treatment, this 20-year-old young man is still alive. Nine of the eleven children in the study saw an improvement in their symptoms. In four of them, the tumor shrank. The average survival time increased by seven months. The study was published in Nature today.
Read the article in De Volkskrant here (behind a paywall).
Dr. Jasper van der Lugt, pediatric oncologist specializing in brain tumors, says: ‘The results are promising, but I am cautious. You had to be well enough and your tumor had to be small enough to take part in this study. And many of the children and young people in the study had received radiation shortly before the CAR-T cell therapy. That makes it hard to untangle the effect of the radiotherapy and the CAR-T treatment.
‘All children and young people in the study experienced serious side effects. With an incurable brain tumor, you sometimes take more risks, but it remains a precarious balance. Children with DIPG usually do not have long to live. It is important to carefully weigh the pros and cons of participating in a study of a new treatment. At the Máxima, we hope to open our own clinical trial at the end of next year into another type of CAR-T for children with a brain tumor, including DIPG.’
Dr. Friso Calkoen, pediatric oncologist specialized in CAR-T, adds: ‘So far, CAR T-cells have mainly worked on forms of blood cancer, such as leukemia. It is more difficult to get them to work in tumors in organs or tissues, because they have a kind of protective wall around them. They are also more difficult to distinguish from healthy tissue around them. All over the world, including here at the Princess Máxima Center, scientists are studying whether this promising form of immunotherapy can also work for brain and solid tumors.’
Works on the tram track at Padualaan in Utrecht Science Park
To make public transport future-proof, Strukton is carrying out works on the tram track on Padualaan in Utrecht Science Park on behalf of the Province of Utrecht. In mid-January, works on the track will start near Weg tot de Wetenschap, just beyond the tram stop.
High-tech robots and laser scanners: this laboratory is where the food of the future is being discovered.
A remarkable world of high-tech robots, laser scanners, climate chambers, and other advanced equipment is hidden inside an inconspicuous, windowless building at Utrecht Science Park—a world entirely focused on the question of how to feed the global population in 2050.
Together in action for 3FM Serious Request and Spieren voor Spieren
During 3FM Serious Request the whole of the Netherlands came into action for Spieren voor Spieren. A lot of money was raised that can really make a difference for children with a muscular disease: the final amount is € 18,423,566. With the money, Spieren voor Spieren can do research on treatment and medication, faster diagnosis and exercise for children with a muscular disease.
Wennink plan: Life Sciences and biotechnology are important growth drivers for the earning capacity of the Netherlands
The Dutch Life Sciences and biotechnology sector can make a much larger contribution to the Netherlands’ economic strength. This is shown in a new growth strategy presented today as part of Peter Wennink’s advisory report. The report also highlights Utrecht Science Park as one of the key innovation locations and sources of progress and growth.